The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Kidney Fibrosis Treatment-Global Market Insights and Sales Trends 2025
Synopsis
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.
The global Kidney Fibrosis Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Kidney Fibrosis Treatment in various end use industries. The expanding demands from the Chronic Kidney Diseases, Kidney Cancer Treatment and Others,, are propelling Kidney Fibrosis Treatment market. Angiotensin Converting Enzyme (ACE) Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pirfenidone segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Kidney Fibrosis Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Kidney Fibrosis Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Kidney Fibrosis Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Kidney Fibrosis Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Kidney Fibrosis Treatment covered in this report include Merck and Co(US), Pfizer Inc(US), F. Hoffman-La Roche(Switzerland), InterMune Inc(US), Galectin Therapeutics(US), La Jolla Pharmaceutical Company(US), ProMetic Life-Sciences Inc(Canada), BioLine Rx(Israel) and Genzyme Corporation(US), etc.
The global Kidney Fibrosis Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck and Co(US)
Pfizer Inc(US)
F. Hoffman-La Roche(Switzerland)
InterMune Inc(US)
Galectin Therapeutics(US)
La Jolla Pharmaceutical Company(US)
ProMetic Life-Sciences Inc(Canada)
BioLine Rx(Israel)
Genzyme Corporation(US)
Global Kidney Fibrosis Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Kidney Fibrosis Treatment market, Segment by Type:
Angiotensin Converting Enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors
Global Kidney Fibrosis Treatment market, by Application
Chronic Kidney Diseases
Kidney Cancer Treatment
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Kidney Fibrosis Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.
The global Kidney Fibrosis Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Kidney Fibrosis Treatment in various end use industries. The expanding demands from the Chronic Kidney Diseases, Kidney Cancer Treatment and Others,, are propelling Kidney Fibrosis Treatment market. Angiotensin Converting Enzyme (ACE) Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Pirfenidone segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Kidney Fibrosis Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Kidney Fibrosis Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Kidney Fibrosis Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Kidney Fibrosis Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Kidney Fibrosis Treatment covered in this report include Merck and Co(US), Pfizer Inc(US), F. Hoffman-La Roche(Switzerland), InterMune Inc(US), Galectin Therapeutics(US), La Jolla Pharmaceutical Company(US), ProMetic Life-Sciences Inc(Canada), BioLine Rx(Israel) and Genzyme Corporation(US), etc.
The global Kidney Fibrosis Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck and Co(US)
Pfizer Inc(US)
F. Hoffman-La Roche(Switzerland)
InterMune Inc(US)
Galectin Therapeutics(US)
La Jolla Pharmaceutical Company(US)
ProMetic Life-Sciences Inc(Canada)
BioLine Rx(Israel)
Genzyme Corporation(US)
Global Kidney Fibrosis Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Kidney Fibrosis Treatment market, Segment by Type:
Angiotensin Converting Enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors
Global Kidney Fibrosis Treatment market, by Application
Chronic Kidney Diseases
Kidney Cancer Treatment
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Kidney Fibrosis Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Kidney Fibrosis Treatment
1.1 Kidney Fibrosis Treatment Market Overview
1.1.1 Kidney Fibrosis Treatment Product Scope
1.1.2 Kidney Fibrosis Treatment Market Status and Outlook
1.2 Global Kidney Fibrosis Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Kidney Fibrosis Treatment Market Size by Region (2018-2029)
1.4 Global Kidney Fibrosis Treatment Historic Market Size by Region (2018-2023)
1.5 Global Kidney Fibrosis Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Kidney Fibrosis Treatment Market Size (2018-2029)
1.6.1 North America Kidney Fibrosis Treatment Market Size (2018-2029)
1.6.2 Europe Kidney Fibrosis Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Kidney Fibrosis Treatment Market Size (2018-2029)
1.6.4 Latin America Kidney Fibrosis Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Kidney Fibrosis Treatment Market Size (2018-2029)
2 Kidney Fibrosis Treatment Market by Type
2.1 Introduction
2.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors
2.1.2 Pirfenidone
2.1.3 Renin Inhibitors
2.1.4 Angiotensin II Receptor Blockers (ARBs)
2.1.5 Vasopeptidase Inhibitors
2.2 Global Kidney Fibrosis Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Kidney Fibrosis Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Kidney Fibrosis Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Kidney Fibrosis Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Kidney Fibrosis Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Kidney Fibrosis Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Kidney Fibrosis Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Kidney Fibrosis Treatment Revenue Breakdown by Type (2018-2029)
3 Kidney Fibrosis Treatment Market Overview by Application
3.1 Introduction
3.1.1 Chronic Kidney Diseases
3.1.2 Kidney Cancer Treatment
3.1.3 Others
3.2 Global Kidney Fibrosis Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Kidney Fibrosis Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Kidney Fibrosis Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Kidney Fibrosis Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Kidney Fibrosis Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Kidney Fibrosis Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Kidney Fibrosis Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Kidney Fibrosis Treatment Revenue Breakdown by Application (2018-2029)
4 Kidney Fibrosis Treatment Competition Analysis by Players
4.1 Global Kidney Fibrosis Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Kidney Fibrosis Treatment as of 2022)
4.3 Date of Key Players Enter into Kidney Fibrosis Treatment Market
4.4 Global Top Players Kidney Fibrosis Treatment Headquarters and Area Served
4.5 Key Players Kidney Fibrosis Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Kidney Fibrosis Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Merck and Co(US)
5.1.1 Merck and Co(US) Profile
5.1.2 Merck and Co(US) Main Business
5.1.3 Merck and Co(US) Kidney Fibrosis Treatment Products, Services and Solutions
5.1.4 Merck and Co(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Merck and Co(US) Recent Developments
5.2 Pfizer Inc(US)
5.2.1 Pfizer Inc(US) Profile
5.2.2 Pfizer Inc(US) Main Business
5.2.3 Pfizer Inc(US) Kidney Fibrosis Treatment Products, Services and Solutions
5.2.4 Pfizer Inc(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Inc(US) Recent Developments
5.3 F. Hoffman-La Roche(Switzerland)
5.3.1 F. Hoffman-La Roche(Switzerland) Profile
5.3.2 F. Hoffman-La Roche(Switzerland) Main Business
5.3.3 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Products, Services and Solutions
5.3.4 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 InterMune Inc(US) Recent Developments
5.4 InterMune Inc(US)
5.4.1 InterMune Inc(US) Profile
5.4.2 InterMune Inc(US) Main Business
5.4.3 InterMune Inc(US) Kidney Fibrosis Treatment Products, Services and Solutions
5.4.4 InterMune Inc(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 InterMune Inc(US) Recent Developments
5.5 Galectin Therapeutics(US)
5.5.1 Galectin Therapeutics(US) Profile
5.5.2 Galectin Therapeutics(US) Main Business
5.5.3 Galectin Therapeutics(US) Kidney Fibrosis Treatment Products, Services and Solutions
5.5.4 Galectin Therapeutics(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Galectin Therapeutics(US) Recent Developments
5.6 La Jolla Pharmaceutical Company(US)
5.6.1 La Jolla Pharmaceutical Company(US) Profile
5.6.2 La Jolla Pharmaceutical Company(US) Main Business
5.6.3 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Products, Services and Solutions
5.6.4 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 La Jolla Pharmaceutical Company(US) Recent Developments
5.7 ProMetic Life-Sciences Inc(Canada)
5.7.1 ProMetic Life-Sciences Inc(Canada) Profile
5.7.2 ProMetic Life-Sciences Inc(Canada) Main Business
5.7.3 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Products, Services and Solutions
5.7.4 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 ProMetic Life-Sciences Inc(Canada) Recent Developments
5.8 BioLine Rx(Israel)
5.8.1 BioLine Rx(Israel) Profile
5.8.2 BioLine Rx(Israel) Main Business
5.8.3 BioLine Rx(Israel) Kidney Fibrosis Treatment Products, Services and Solutions
5.8.4 BioLine Rx(Israel) Kidney Fibrosis Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 BioLine Rx(Israel) Recent Developments
5.9 Genzyme Corporation(US)
5.9.1 Genzyme Corporation(US) Profile
5.9.2 Genzyme Corporation(US) Main Business
5.9.3 Genzyme Corporation(US) Kidney Fibrosis Treatment Products, Services and Solutions
5.9.4 Genzyme Corporation(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Genzyme Corporation(US) Recent Developments
6 North America
6.1 North America Kidney Fibrosis Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Kidney Fibrosis Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Kidney Fibrosis Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Kidney Fibrosis Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Kidney Fibrosis Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Kidney Fibrosis Treatment Market Dynamics
11.1 Kidney Fibrosis Treatment Industry Trends
11.2 Kidney Fibrosis Treatment Market Drivers
11.3 Kidney Fibrosis Treatment Market Challenges
11.4 Kidney Fibrosis Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
